- Home
- MYGN vs EVV Comparison
MYGN vs EVV Comparison
Compare MYGN & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- EVV
- Stock Information
- Founded
- MYGN 1991
- EVV 2003
- Country
- MYGN United States
- EVV United States
- Employees
- MYGN N/A
- EVV N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EVV Finance/Investors Services
- Sector
- MYGN Health Care
- EVV Finance
- Exchange
- MYGN Nasdaq
- EVV Nasdaq
- Market Cap
- MYGN 1.3B
- EVV 1.2B
- IPO Year
- MYGN 1995
- EVV N/A
- Fundamental
- Price
- MYGN $8.80
- EVV $10.14
- Analyst Decision
- MYGN Hold
- EVV
- Analyst Count
- MYGN 15
- EVV 0
- Target Price
- MYGN $20.43
- EVV N/A
- AVG Volume (30 Days)
- MYGN 875.3K
- EVV 323.7K
- Earning Date
- MYGN 05-06-2025
- EVV 01-01-0001
- Dividend Yield
- MYGN N/A
- EVV 9.66%
- EPS Growth
- MYGN N/A
- EVV N/A
- EPS
- MYGN N/A
- EVV N/A
- Revenue
- MYGN $837,600,000.00
- EVV N/A
- Revenue This Year
- MYGN $3.03
- EVV N/A
- Revenue Next Year
- MYGN $8.31
- EVV N/A
- P/E Ratio
- MYGN N/A
- EVV N/A
- Revenue Growth
- MYGN 11.21
- EVV N/A
- 52 Week Low
- MYGN $8.53
- EVV $8.52
- 52 Week High
- MYGN $29.30
- EVV $10.07
- Technical
- Relative Strength Index (RSI)
- MYGN 27.06
- EVV 53.07
- Support Level
- MYGN $8.53
- EVV $9.97
- Resistance Level
- MYGN $10.30
- EVV $10.18
- Average True Range (ATR)
- MYGN 0.44
- EVV 0.08
- MACD
- MYGN -0.01
- EVV 0.01
- Stochastic Oscillator
- MYGN 15.08
- EVV 80.48
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure among others.